Last updated: March 28, 2025
Sponsor: LifeNet Health
Overall Status: Active - Recruiting
Phase
N/A
Condition
N/ATreatment
Vivigen Cellular Bone Matrix
Clinical Study ID
NCT04299022
CR-20-002
All Genders
Study Summary
Eligibility Criteria
Inclusion
Prospective Cohort Inclusion Criteria:
- Any skeletally mature patient treated with Vivigen bone graft in the setting of anacute fracture, delayed, non-union or fusion setting will be eligible for inclusion.
Retrospective Cohort Inclusion Criteria:
- Any skeletally mature patient treated with adjunct bone graft in the setting of anacute fracture, delayed, non-union or fusion setting will eligible for inclusion.
Exclusion
Prospective Cohort Exclusion Criteria:
Patients unable to understand either an English or Spanish consent will be excluded.
Patients unable to consent secondary to dementia and/or other mental/psychiatricdiagnoses will be excluded.
Study Design
Total Participants: 250
Treatment Group(s): 1
Primary Treatment: Vivigen Cellular Bone Matrix
Phase:
Study Start date:
June 01, 2021
Estimated Completion Date:
July 31, 2026
Study Description
Connect with a study center
OrlandoHealth
Orlando, Florida 32806
United StatesActive - Recruiting
RWJBarnabas Health
Jersey City, New Jersey 07302
United StatesSite Not Available
Duke University Medical Center
Durham, North Carolina 27710
United StatesActive - Recruiting
Sentara Hospitals
Norfolk, Virginia 23507
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.